Ever Supreme Bio Technology Co. Ltd
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. It operates in two segments: Cell Preparation Business and Other Operating Business segments. The company's products include umbilical cord mesenchymal stem cells (UMC01), a drug candidate in Phase I clinical trials for the… Read more
Ever Supreme Bio Technology Co. Ltd (6712) - Total Assets
Latest total assets as of June 2024: NT$1.80 Billion TWD
Based on the latest financial reports, Ever Supreme Bio Technology Co. Ltd (6712) holds total assets worth NT$1.80 Billion TWD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ever Supreme Bio Technology Co. Ltd - Total Assets Trend (2020–2023)
This chart illustrates how Ever Supreme Bio Technology Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ever Supreme Bio Technology Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2023)
Ever Supreme Bio Technology Co. Ltd's total assets of NT$1.80 Billion consist of 73.3% current assets and 26.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 16.2% |
| Accounts Receivable | NT$109.01 Million | 5.3% |
| Inventory | NT$69.09 Million | 3.3% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2020–2023)
This chart illustrates how Ever Supreme Bio Technology Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ever Supreme Bio Technology Co. Ltd's current assets represent 73.3% of total assets in 2023, an increase from 55.8% in 2020.
- Cash Position: Cash and equivalents constituted 16.2% of total assets in 2023, up from 8.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 5.3% of total assets.
Ever Supreme Bio Technology Co. Ltd Competitors by Total Assets
Key competitors of Ever Supreme Bio Technology Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Ever Supreme Bio Technology Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Ever Supreme Bio Technology Co. Ltd generates 0.37x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Ever Supreme Bio Technology Co. Ltd generates $ 25.98 in net profit.
Ever Supreme Bio Technology Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.65 | 8.08 | 8.08 |
| Quick Ratio | 3.21 | 7.61 | 7.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$624.95 Million | NT$ 1.24 Billion | NT$ 1.32 Billion |
Ever Supreme Bio Technology Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Ever Supreme Bio Technology Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.71 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 5.2% |
| Total Assets | NT$2.08 Billion |
| Market Capitalization | $268.60 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ever Supreme Bio Technology Co. Ltd's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Ever Supreme Bio Technology Co. Ltd's assets grew by 5.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ever Supreme Bio Technology Co. Ltd (2020–2023)
The table below shows the annual total assets of Ever Supreme Bio Technology Co. Ltd from 2020 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | NT$2.08 Billion | +5.18% |
| 2022-12-31 | NT$1.97 Billion | -2.42% |
| 2021-12-31 | NT$2.02 Billion | +135.65% |
| 2020-12-31 | NT$858.32 Million | -- |